GLSI
Greenwich LifeSciences, Inc.Company Information
- Company Name
- Greenwich LifeSciences, Inc.
- CIK
- CIK0001799788
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- GLSI: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- GLSI
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-07-29
- Last sale
- —
- Shares purchased (TTM)
- 36,800
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,684,686
- Shares outstanding
- 14,621,230
- Ownership
- 11.52%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 2.57%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash | 9 | 11 | 6 | 4 | 3 | 3 | 4 | 6 | 7 | 6 | 7 | 9 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 9 | 11 | 6 | - | - | - | 4 | - | - | - | - | - | ||||||
| Finite Lived Intangible Assets Net | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 9 | 11 | 6 | 4 | 3 | 3 | 4 | 6 | 7 | 6 | 7 | 9 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 5 | 5 | 5 | 1 | 1 | 1 | 3 | 1 | 1 | 0 | 0 | 0 | ||||||
| Deferred Compensation Liability Current And Noncurrent | - | 1 | 1 | - | - | 0 | 0 | - | - | - | - | - | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 6 | 5 | 6 | 2 | 2 | 1 | 3 | 1 | 1 | 0 | 0 | 0 | ||||||
| Deferred Compensation Liability Current | 1 | - | - | 0 | - | - | - | - | - | - | - | - | ||||||
| Employee Related Liabilities Current | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 6 | 5 | 6 | 2 | 2 | 1 | 3 | 1 | 1 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital Common Stock | 100 | 98 | 87 | 80 | 75 | 71 | 69 | 63 | 61 | 58 | 57 | 56 | ||||||
| Stockholders Equity | 3 | 5 | 0 | 2 | 1 | 0 | 1 | 5 | 6 | 5 | 7 | 9 | ||||||
| Retained Earnings Accumulated Deficit | -97 | -93 | -87 | -78 | -73 | -69 | -68 | -58 | -55 | -53 | -50 | -48 | ||||||
| Liabilities And Stockholders Equity | 9 | 11 | 6 | 4 | 3 | 3 | 4 | 6 | 7 | 6 | 7 | 9 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 15 | 15 | 14 | 14 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | ||||||
| Shares Outstanding | 15 | 15 | 14 | 14 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialGreenwich LifeSciences, Inc. (GLSI) — SEC Financial Statements & Analysis
Greenwich LifeSciences, Inc. (GLSI) is a pharmaceutical preparations company, incorporated in DE. Greenwich LifeSciences, Inc. trades on Nasdaq as: GLSI. Greenwich LifeSciences, Inc. (GLSI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Greenwich LifeSciences, Inc. carries a market cap of $343.01M, a P/E ratio of -15.27x, a P/B ratio of 110.05x, an enterprise value of $334.14M, and an EV/EBITDA multiple of -14.75x. On profitability, it posts a Return on Equity (ROE) of -1207.69% and a Return on Assets (ROA) of -253.15%. Per share, it reports EPS of $-1.54, diluted EPS of $-1.54, free cash flow per share of $-0.85, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 19.35% year-over-year and EPS growth of 9.14% year-over-year. On the balance sheet, it maintains a current ratio of 1.54x, a quick ratio of 1.54x, working capital of $3.12M, a debt-to-equity ratio of 1.85x, a debt ratio of 0.65, free cash flow of $-12.49M (TTM), and net debt of $-8.88M. Figures sourced from SEC EDGAR.
- Market Cap
- $343.01M
- P/E TTM
- -15.27x
- EPS TTM
- $-1.54
- P/B TTM
- 110.05x
- ROE TTM
- -1207.69%
- ROA TTM
- -253.15%
- Debt To Equity
- 1.85x
- Free Cash Flow TTM
- $-12.49M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Greenwich LifeSciences, Inc. in?
Greenwich LifeSciences, Inc. (GLSI) operates in the Pharmaceutical Preparations industry.
What exchange does GLSI trade on?
Greenwich LifeSciences, Inc. (GLSI) trades on the Nasdaq.
Where is Greenwich LifeSciences, Inc. incorporated?
Greenwich LifeSciences, Inc. is incorporated in DE.
When was Greenwich LifeSciences, Inc. (GLSI)'s most recent SEC filing?
Greenwich LifeSciences, Inc. (GLSI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is GLSI's market cap?
Greenwich LifeSciences, Inc. (GLSI) has a market capitalization of $343.01M as of 2026-06-30.
What is GLSI's EPS (earnings per share)?
Greenwich LifeSciences, Inc. (GLSI)'s trailing twelve month EPS is $-1.54 as of 2026-06-30.
What is GLSI's ROE (return on equity)?
Greenwich LifeSciences, Inc. (GLSI)'s trailing twelve month Return on Equity (ROE) is -1207.69% as of 2026-06-30.
What is GLSI's ROA (return on assets)?
Greenwich LifeSciences, Inc. (GLSI)'s trailing twelve month Return on Assets (ROA) is -253.15% as of 2026-06-30.
What is GLSI's EV/EBITDA?
Greenwich LifeSciences, Inc. (GLSI)'s trailing twelve month EV/EBITDA is -14.75x as of 2026-06-30.